Recent Event
Skye Bioscience Virtual KOL Event
Company Overview
Skye Bioscience (Nasdaq: SKYE) is a biopharmaceutical company focused on unlocking new therapeutic pathways to improve metabolic health. Backed by specialist life science investors, Skye is leveraging biologic targets with substantial human proof of mechanism for the development of first-in-class therapeutics with significant clinical and commercial differentiation. Skye plans to launch its CBeyondTM Phase 2 clinical trial in obesity in Q3 2024 for Nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors. This study will compare Nimacimab to placebo and in separate treatment arms, Wegovy® + Nimacimab compared to Wegovy® + placebo. Skye expects interim and topline data from its Phase 2 study in 2025.
Latest News
IR Contacts
Company
Skye Bioscience, Inc.
11250 El Camino Real
Suite 100
San Diego, CA 92130
Investor Relations
SKYE Investor Relations
T: (858) 410-0266
ir@skyebioscience.com
Transfer Agent
ClearTrust, LLC
16540 Pointe Village Dr.
Suite 210
Lutz, FL 33558
T: 813-235-4490
www.ClearTrustOnline.com
Market Data copyright © 2024 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.